IRCCS Humanitas Research Hospital & Humanitas University
Published February 4, 2021 | Version v1
Dataset Restricted

Dataset related to article "Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin Lymphomas"

Authors/Creators

  • 1. Institut Paoli Calmettes
  • 2. IRCCS Humanitas Research Hospital
  • 3. Institut Paoli Calemttes
  • 4. IRCCS Humanitas Research Hospital AND Humanitas University, Department of Biomedical Sciences, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele – Milan, Italy

Description

This record contains data related to article Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin Lymphomas

Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a valid option in patients with refractory lymphomas.
HLA haploidentical stem cell transplantation (haplo-SCT) expanded the accessibility to allogeneic hematopoietic
cell transplantation. The aims of study were to retrospectively assess the toxicity and efficacy of haplo-SCT
using nonmyeloablative conditioning in patients with advanced lymphoma. In total, 147 patients with advanced
lymphoma at 2 partner institutions were included. Patients received a uniform nonmyeloablative conditioning
regimen and graft-versus-host disease (GVHD) prophylaxis. The primary endpoints were progression-free survival
(PFS), overall survival (OS), GVHD, nonrelapse mortality, and GVHD, relapse-free survival (GRFS). Median follow-
up was 39 months (range, 6 to 114 months). The median age was 46 years (range, 19 to 71 years). Sixty-five
percent of patients were in complete remission (CR) at transplantation. Cumulative incidence of grade II to IV
acute GVHD was 30% (95% confidence interval [Cl], 23% to 38%). Two-year cumulative incidence of all grades of
chronic GVHD was 13% (95% CI, 8% to 20%). Two-year cumulative incidence of disease relapse was 19% (95% CI,
14% to 27%), with a higher incidence in patients not being in CR at allo-HCT (CR versus not CR: 12% versus 33%,
P = .006). Two-year PFS, OS, and GRFS were 66% (95% CI, 59-75), 73% (95% CI, 66-81), and 56% (95% CI, 48-65),
respectively. Haplo-SCT with post-transplantation cyclophosphamide may be considered a valid option for
patients with aggressive lymphoma and deserves further evaluation.

Files

Restricted

The record is publicly accessible, but files are restricted to users with access.

Request access

If you would like to request access to these files, please fill out the form below.

You need to satisfy these conditions in order for this request to be accepted:

This set of data is accessible only upon request because it includes sensitive data.

Please write your request at biblioteca@humanitas.it

You are currently not logged in. Do you have an account? Log in here

Additional details

Related works

Is supplement to
10.1016/j.bbmt.2020.08.014 (DOI)
Is supplemented by
32822845 (PMID)